Steven Frisch
Analyst · Anja Soderstrom. Your line is open
Thank you, Todd. Good morning. I will start on Slide 7 with a review of the fiscal fourth quarter and the full fiscal year performance of our market sectors for 2021, as well as our expectations for the sectors for the fiscal first quarter of 2022. Customer demand across our market sectors was very robust in 2021, including the fiscal fourth quarter. However, global supply chain constraints as well as operational inefficiencies due to COVID-19 in our Malaysia operations were worse than anticipated. As a result, all three of our sectors missed revenue expectations for the fiscal fourth quarter, largely due to these challenges. In spite of the many obstacles in fiscal 2021, our Healthcare/Life Sciences and Industrial sectors achieved annual revenue growth of 5% and 2%, respectively. This was largely due to successfully ramping new programs throughout the year. Although our Aerospace and Defense sector was also ramping new programs, the headwinds associated with commercial aerospace were too large to overcome. The result in revenue is a decline of almost 20% for Aerospace and Defense sector. The net result is, the teams generated Plexus revenue in fiscal 2021 that was slightly below our record of $3.4 billion in fiscal 2022. As we start fiscal 2022, we believe the COVID-19 situation in Malaysia is improving. However, the global supply chain constraints will limit our ability to capture the broad-based, robust demand from customers in the fiscal first quarter. Looking at our Industrial sector, demand in most subsectors, including semiconductor capital equipment, warehouse automation and communications remain strong. However, supply chain constraints are limiting our ability to realize the full potential. As a result, we expect a low single-digit decrease in our Industrial sector for the fiscal first quarter. In our Healthcare/Life Sciences sector, a new ramp of an aftermarket services program and a robotic-assisted medical device are enabling growth. The result is, we expect a mid-single-digit increase for our Healthcare/Life Science sector in the fiscal first quarter. Customer forecast in our Aerospace and Defense sector are strengthening, we expect the commercial aerospace and commercial space subsectors to continue to increase this trend in fiscal 2022. Unfortunately, supply chain challenges are limiting our ability to capture the demand within the fiscal first quarter. As a result, we expect a low single-digit decrease for our Aerospace and Defense sector in the fiscal first quarter. Please advance to Slide 8 for an overview of our wins performance for the fiscal fourth quarter. We won 38 new manufacturing programs that we expect to generate $251 million in annualized revenue when fully ramped into production. For fiscal 2021, the wins total exceeded $1 billion, which is a fiscal year record. In addition, the strong wins performance throughout fiscal 2021 increased our wins momentum, which is defined as the trailing four quarters of wins divided by the trailing four quarters of revenue. At 31%, the wins momentum is well beyond our 25% goal and supports our growth strategy. We can advance to Slide 9 to review the manufacturing wins by region for the fiscal fourth quarter. The Americas region wins were an impressive $142 million in the fiscal fourth quarter. The strong wins result was driven by programs that either require or strongly desire a U.S. manufacturing solution. In spite of the COVID-19 distraction during the quarter, the APAC region headwinds of $62 million in the fiscal fourth quarter. The region's track record of strong performance is supporting new wins, in spite of the inability for customers to easily visit these sites. The major reason finished fiscal 2021 with their highest quarterly wins of $47 million in the fiscal fourth quarter. Included in the wins are two new logos that we expect to ramp within fiscal 2022 in our Kelso, Scotland facility. Please advance to Slide 10 for further insight into the manufacturing wins performance by market sector. The Industrial sector wins increased to $87 million in the fiscal fourth quarter. Robust wins in the semiconductor capital equipment and communications subsectors enabled then a stronger result. Our Healthcare/Life Sciences sector generated $44 million of wins in the fiscal fourth quarter. Although a lower-than-typical wins result for the sector, it is partly a timing issue, and we anticipate a meaningful increase in the fiscal first quarter wins for the sector. The Aerospace and Defense sector had exceptionally strong wins totaling $120 million in the fiscal fourth quarter. New programs in the commercial space subsector enabled the strong outcome. These wins drove a 31% or $61 million increase into the sector's trailing 4-quarter wins, which closed the fiscal fourth quarter at a very healthy $258 million. Please advance to Slide 11 for further insight into the some of the fiscal fourth quarter wins. Including the industrial wins, it's a next-generation cable access program that our customer has decided to dual source with their internal manufacturing to mitigate long-term business continuity risk. The product will be produced by our Guadalajara Mexico operations. The industrial team also added a new Communications customer who produces a broad portfolio of connectivity products. Our team in Penang, Malaysia will be producing the first assembly, a data compression and security product, with this new customer. In addition to these communication opportunities, the Industrial sector expanded market share with an existing semiconductor capital equipment customer. The products, which are used in the front end processing of semiconductor wafers, will be built in our Portland, Oregon and our Guadalajara, Mexico facilities. The Healthcare/Life Sciences team expanded our portfolio in the differentiated market of robotic-assisted medical instruments with another meaningful win from an existing customer. This new device will be produced in our Nina, Wisconsin facility. The Healthcare/Life Sciences team also added a diagnostic tester program from a new customer in the EMEA region. The COVID PCR tester will be produced in our Kelso, Scotland facility. Included in the Aerospace wins are two satellite communication programs that we expect to add meaningful revenue to our growing space subsector. The first opportunity significantly expands our relationship with a customer in our Boise, Idaho facility, while the second opportunity is with a new customer for our Kelso, Scotland facility. With this latest win in EMEA, we expect to be producing commercial space programs in all three of our regions in fiscal 2022. We can proceed to Slide 12 for highlights of our funnel of qualified manufacturing opportunities. Our funnel grew over $200 million in the fiscal fourth quarter to finish at a record $3.3 billion. Our industrial sector led the increase by expanding this funnel by an impressive $265 million to close the fiscal fourth quarter at $938 million. Three larger RF communication programs from an existing customer drove the significant increase. The Healthcare/Life sciences sector held their funnel at a very healthy $1.7 billion. Two larger manufacturing opportunities, including an ultrasound device and a robotic-assisted medical device, were the significant new program adds in the quarter. In addition to the exceptional wins in the fiscal fourth quarter, the Aerospace and Defense sector added $37 million to their funnel to exit fiscal 2021 with a robust funnel of $708 million. New opportunities in the commercial and defense subsectors not only backfilled the wins, but fuel the funnel's growth. Next, I would like to turn to operating performance on Slide 13. The highlight of the fiscal fourth quarter and the full fiscal year of 2021 for me is the team's operational performance in the midst of a global pandemic. The team's ability to generate GAAP operating margin of 5% for the fiscal fourth quarter and 5.2% for the full fiscal year is outstanding. The performance of result of teamwork, our manufacturing, engineering, aftermarket services, market sector, supply chain and corporate teams collaborated and supported each other. Each time a new challenge presented itself, the team rallied to mitigate the issue for our customers and our shareholders. As we look to the fiscal first quarter, the teamwork carries on. We continue to make investments in new program ramps and facilities that will enable future growth. In addition, we continue to maintain additional resources to help mitigate component constraint challenges and the operational inefficiencies COVID-19 has created. Even with the additional burdens, the team is committed to working together to deliver strong operating results with operating margin in the range of 4.6% to 5% for the fiscal first quarter. A few final comments. I typically highlight an example of dedication and outstanding performance of the Plexus team each quarter. This quarter, our customers have done it for me. In addition to a recent letter of commendation from one of our largest Healthcare/Life Sciences customers regarding exceptional performance during the pandemic, one of our largest industrial customers presented us with a supplier award for outstanding performance as well. I will leave you with a few of the remarks that came with the award. The customer noted that they would like to recognize Plexus for outstanding performance responding to an unprecedented ramp during the global COVID crisis. They also commented that we increased capacity by 160% amid continuous disruptions in labor, material and equipment availability. I believe the customer captured the current environment very well and how our teams are responding. I would like to thank the Plexus team for not just their efforts each day, but for the results they are creating. I will now turn the call to Pat for an in-depth review of our financial performance. Pat?